Now, a study suggests simple blood test could help predict those who will benefit. The analysis by US biotech Circular Genomics focuses on an assay that looks for a circular RNA (circRNA) blood ...
The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a delay to its review earlier ...
Our round-up of recent biotech financings is headed by a sizeable $200 million third round for Zenas BioPharma, with Cellectis, Reunion Neuroscience, Karius, Context Therapeutics, and Enlaza also ...
Ariel Buda-Levin, MSc, is President of Medical Communications across Area23 on Hudson, ProHealth, and Trio, as well as the Commercial Medical Communications Champion at IPG Health Network. A ...
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another study.
Understanding complex scientific studies is often a challenge for patients as well as healthcare professionals, but one that may become easier thanks to artificial intelligence. A new study has shown ...
Late last month, pharmaphorum was invited on an IDA Ireland-organised press tour of the life sciences industry in Ireland’s West, permitting an inside peek into the world-class life sciences ...
Alpibectir was developed in a public-private collaboration between GSK, Pasteur Institute Lille, and the University of Lille, and is designed as a companion to ethionamide (Eto), which is an important ...
The Novo Nordisk Foundation, the Bill & Melinda Gates Foundation, and Wellcome have joined forces to tackle some of the most ...
Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regulators about the design of a ...
Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regulators about the design of a ...
Shah Capital is among the top three investors in Novavax, with a 7.5% stake that has swelled from 6.7% when it first launched its campaign against the company’s leadership last month. It had vowed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results